* Vaxcel Inc., of Atlanta, received two grants totaling $200,000 from the National Institutes of Health (NIH). One grant, from the NIH's Small Business Technology Transfer program, will be used to develop mucosal delivery of DNA vaccines. The other, from the NIH's Small Business Innovation Research program, is targeted for development of Vaxcel's Optivax adjuvant to improve influenza vaccines. Vaxcel is a subsidiary of CytRx Corp., of Atlanta.
* Genetics Institute Inc., of Cambridge, Mass., entered an agreement with Chugai Pharmaceutical Co. Ltd., of Tokyo, granting the Japanese pharmaceutical firm access to Genetics Institute's DiscoverEase library of uncharacterized, secreted proteins for drug discovery. Chugai is the sixth participant in the DiscoverEase program.